Compositions and methods for inhibiting intercellular interactions
AssigneeLubris LLC
InventorsGregory D. Jay, Tannin Schmidt, Benjamin Sullivan
Life of this patent
Estimating the term…
Loading patent…
AssigneeLubris LLC
InventorsGregory D. Jay, Tannin Schmidt, Benjamin Sullivan
Estimating the term…
Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature. In these instances PRG4 glycoprotein adheres to extracellular matrix or cell surfaces and presents a glycol-surface of polysaccharide which blocks the mechanisms of cell motility, extravasation, or intravazation, inhibits sticking of macrophages and platelets, and/or serves as a substitute or mimic of native glycocalyx.
A method of treating fibrosis of an organ or tissue in a patient suffering from or at risk of fibrosis comprising administering directly or indirectly to a site in the patient having or at risk of fibrosis an amount of PRG4 in a physiologically compatible carrier sufficient to prevent or slow development or progression of fibrosis, wherein the site having or at risk of fibrosis is a site affected by cirrhosis of the liver, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, myelofibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphatic tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis.
A method of treating fibrosis of an organ or tissue in a patient suffering from or at risk of fibrosis comprising administering directly or indirectly to a site in the patient having or at risk of fibrosis an amount of PRG4 in a physiologically compatible carrier sufficient to prevent or slow development or progression of fibrosis, wherein the site having or at risk of fibrosis is the site of a surgical incision,
Dependencies are inferred from the claim text.